IL0011552663 - Common Stock - After market: 1.55 -0.07 (-4.32%)
NASDAQ:GMDA (1/27/2023, 7:11:08 PM)+0.07 (+4.52%)
|GICS Sector||Health Care|
|Earnings (Last)||11-14 2022-11-14/bmo||Earnings (Next)||N/A N/A|
|Ins Owners||1.13%||Inst Owners||31.96%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
GAMIDA CELL LTD
PO Box 34670
CEO: Julian Adams
Israel-based biotech Gamida Cell Ltd. (GMDA) lost ~21% in the pre-market trading Tuesday after announcing that the U.S
It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday morning!
Here you can normally see the latest stock twits on GMDA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.